This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Community Health (CYH) Sells Three Florida Facilities for $294M
by Zacks Equity Research
Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) on consistent growth performance and raised guidance.
McKesson (MCK) Announces Availability of FDA-Cleared Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for breast cancer.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Why Is Tandem Diabetes Care, Inc. (TNDM) Up 33.2% Since Last Earnings Report?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Revvity (RVTY) Launches New Molecular Testing for Newborns
by Zacks Equity Research
Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Here's Why Investors Should Hold Humana (HUM) Stock for Now
by Zacks Equity Research
Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Zacks.com featured highlights DaVita, Brinker International, CNA Financial and Integer Holdings
by Zacks Equity Research
DaVita, Brinker International, CNA Financial and Integer Holdings have been highlighted in this Screen of The Week article.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered
by Zacks Equity Research
Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like DVA, EAT, CNA and ITGR that are seeing price strength have a high chance of carrying the momentum forward.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.
Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.